MMV: The next 10 years

Chris Hentschel, President & CEO
Medicines for Malaria Venture
Ahead of the curve:

“Our view is that provided **we** all work together, eschewing narrow interests, doctrines, and competition, we can make something remarkable happen – we can be the generation that defeats malaria. The time to set a realistic timetable to finish this job is long overdue.”

MMV’s **2006** Annual Report.
Who are we?”

**Multilaterals**
- UNDP
- ADB
- WHO
- UNICEF

**Donor Countries**
- France
- Netherlands
- Japan

**NGOs**
- Kenam
- MnM
- PSI
- SFH

**Malaria Endemic Countries**

**Private Sector**
- ExxonMobil
- Merck
- PATH

**Research & Academia**

**Foundations**
- Clinton Global Initiative
- Gates Foundation

**Ex officio members**
- UN Special Envoy for Malaria
From the Global Malaria Action Plan

By 2030, treatment is <1% of total costs due to lower incidence

But standard of care therapy is evolving:

- Presumptive Monotherapy
- Presumptive Combination Therapy
- Diagnosed Therapy?
- Diagnosed Therapy Including Asymptomatic Patients?

2010 → ??

Medicines for Malaria Venture
… after 2010 the next chapter is becoming clearer

Chapter 1
2000 - 2010
• Discover
• Develop
• Deliver

Chapter 2
2010 - 2020
• Influence
• Innovate
• Integrate
Thank You

危機

Danger   Opportunity
Ten more years….

Medicines for Malaria Venture